戴纳基 DYN 深 沪
已收盘 12-12 16:00:00 美东时间
19.27
-0.150
-0.77%
华盛通- 最 高19.9599
- 今 开19.51
- 成交量 445.41万股
- 最 低 19.20
- 昨 收 19.42
- 总市值 27.36亿
- 52周最高 26.22
- 市盈率 静 --
- 换手率 3.14%
- 52周最低 6.36
- 委 比 -56.47%
- 总股本 1.42亿
- 历史最高 47.45
- 量 比 0.73
- 振 幅 3.91%
- 历史最低 4.30
- 每 手 1
- 风险率 4.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dynex Capital 6.9% Prfd Series C declares $0.6143 dividend
Dynex Capital 6.9% Prfd Series C (DX.PR.C) declares $0.6143/share quarterly dividend. Forward yield 9.48% Payable Jan. 15; for shareholders of record Jan. 1; ex-div Jan. 1. See DX.PR.C Dividend Scorec...
12-12 21:43
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Dyne Therapeutics Announces Upsized Public Offering
An announcement from Dyne Therapeutics ( ($DYN) ) is now available. On December...
12-11 05:51
Dyne Therapeutics prices $350 stock offering
Dyne Therapeutics (DYN) priced an upsized underwritten public offering of 18.98M shares at af $18.44 per share. The gross proceeds are expected to be $350.0 million. The offering is expected to close...
12-10 14:39
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Salesforce ends in red after six-session rally
Salesforce (CRM) snapped six straight sessions of gains on Monday after its shares settled 0.40% lower at $259.53. The company ended in the green in each session between November 28 and December 5. It...
12-09 05:17
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
Dyne Therapeutics plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of z-rostudirsen on December 8, 2025, and host a webcast at 8:00 a.m. ET. A press release will be issued prior to the event. The webcast and an accompanying slide presentation will be available on the Events & Presentations page of Dyne’s investors website, with a replay accessible for 90 days. Dyne focuses on...
12-07 16:00
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points o...
11-18 00:39
